Single-use market to reach $20.8bn by 2026
Analysts from Markets & Markets today released the report "Single use Bioprocessing Market by Product.
ADVERTISEMENT
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 2128 entries already.
Entries by Thomas Gabrielczyk
Study shows advantages of cellular agriculture
Novel foods derived from cell culture instead of animals reduce the environmental impact of diets, water and land use by 80%, report Finnish researchers.
EMA delays Valneva vaccine approval
The approval of Valneva’s Corona vaccine is delaying. The European Medicines Agency’s CHMP requested additional data.
Mimetas BV participating in €325m cancer funding
Organ-on-chip disease model specialist Mimentas BV participates in a €325m funding to accelerate preclinical cancer R&D in the Netherlands.
Hansa Biopharma’s imlifidase advances to Phase III testing
The US Food & Drug Administration has given the green light for Phase III testing of Hansa Biopharma’s imlifidase in anti-GBM disease.
GSK acquires Sierra Oncology for 1.9bn
GlaxoSmithKline acquires California-based Sierra Oncology and a ready-for-approval product candidate for myelofibrosis.
Scientists print 3D cancer model
A 3D tumour model developed by scientists enables drug screening in metastases
Vetter wins at the 2022 CMO Leadership Awards
Vetter, a globally operating CDMO, won the 2022 CMO Leadership Awards in all six core categories – quality, expertise, compatibility, capabilities, reliability and service. Vetter also achieved Champion status in the areas of quality, expertise and compatibility. The award, now in its eleventh year, was given by the leading trade press publication, Life Science Leader.
Affimed prices public offering to finance NK cell trials
Following phantastic AFM13 data at AACR, Affimed N.V. prices it public offering at $84.4m.
GeNeuro finds biologic against post-COVID syndrome
Swiss neurology specialist GeNeuro SA present first data linking silent COVID-19-induced inflammations to neuropsyciatric diseases.